Bioventus (BVS) Net Cash Flow Growth (1y) (2021 - 2026)
Bioventus (BVS) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | -54.17% |
| 10 | Bioventus | 964.42 Mn | 934.96 Mn | 105.67 Mn | -160.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -160.76% |
| Mar 28, 2026 | 23.04% |
| Dec 31, 2025 | 1,465.85% |
| Sep 27, 2025 | -9.10% |
| Jun 28, 2025 | 36.82% |
| Mar 29, 2025 | -70.80% |
| Dec 31, 2024 | -94.15% |
| Sep 28, 2024 | 347.35% |
| Jun 29, 2024 | 212.30% |
| Mar 30, 2024 | -166.26% |
| Dec 31, 2023 | 319.23% |
| Sep 30, 2023 | 22.29% |
| Jul 1, 2023 | 84.44% |
| Apr 1, 2023 | 202.94% |
| Dec 31, 2022 | 86.01% |
| Oct 1, 2022 | 20.49% |
| Jul 2, 2022 | -583.78% |
| Apr 2, 2022 | -138.49% |
| Dec 31, 2021 | -329.85% |
| Oct 2, 2021 | 87.15% |